Targeted Glioma Therapy—Clinical Trials and Future Directions

Aleksandr Shikalov, Igor Koman, Natalya M. Kogan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Glioblastoma multiforme (GBM) is the most common type of glioma, with a median survival of 14.6 months post-diagnosis. Understanding the molecular profile of such tumors allowed the development of specific targeted therapies toward GBM, with a major role attributed to tyrosine kinase receptor inhibitors and immune checkpoint inhibitors. Targeted therapeutics are drugs that work by specific binding to GBM-specific or overexpressed markers on the tumor cellular surface and therefore contain a recognition moiety linked to a cytotoxic agent, which produces an antiproliferative effect. In this review, we have summarized the available information on the targeted therapeutics used in clinical trials of GBM and summarized current obstacles and advances in targeted therapy concerning specific targets present in GBM tumor cells, outlined efficacy endpoints for major classes of investigational drugs, and discussed promising strategies towards an increase in drug efficacy in GBM.

Original languageAmerican English
Article number100
JournalPharmaceutics
Volume16
Issue number1
DOIs
StatePublished - Jan 2024
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2024 by the authors.

Keywords

  • anticancer
  • brain tumors
  • glioma
  • targeted therapy

Fingerprint

Dive into the research topics of 'Targeted Glioma Therapy—Clinical Trials and Future Directions'. Together they form a unique fingerprint.

Cite this